logo
logo

Gamida Cell Announces Entry Into Commitment Letter With Highbridge For $25 Million Financing

Gamida Cell Announces Entry Into Commitment Letter With Highbridge For $25 Million Financing

09/28/22, 4:11 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$25 million
Industry
therapeutics
medical
biotechnology
health care
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), pursuant to which Highbridge has committed to provide a $25 million senior secured, convertible term loan (the “term loan”).

Company Info

Company
Gamida Cell
Location
boston, massachusetts, united states
Additional Info
Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Related People